更新于：2024-12-12
Acetylcysteine
乙酰半胱氨酸
更新于：2024-12-12
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C5H9NO3S |
InChIKeyPWKSKIMOESPYIA-BYPYZUCNSA-N |
CAS号616-91-1 |
关联
817
项与 乙酰半胱氨酸 相关的临床试验Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study
Evaluation of the effects of a four-drug regimen with N-acetylcysteine and comparing it with a four-drug regimen in eradicating Helicobacter pylori in patients with Helicobacter pylori infection
Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)
100 项与 乙酰半胱氨酸 相关的临床结果
登录后查看更多信息
100 项与 乙酰半胱氨酸 相关的转化医学
登录后查看更多信息
100 项与 乙酰半胱氨酸 相关的专利（医药）
登录后查看更多信息
23,420
项与 乙酰半胱氨酸 相关的文献（医药）2025-04-01BIOMATERIALS
3D printing incorporating gold nanozymes with mesenchymal stem cell-derived hepatic spheroids for acute liver failure treatment
Article
作者: Chen, Xiaodie ; Xu, Yanteng ; Tao, Yu ; Li, Mingqiang ; Yi, Ke ; Jin, Yuanyuan ; Zhang, Jiabin ; Xue, Tiantian ; Wang, Haixia ; Lao, Yeh-Hsing ; Li, Fenfang ; Chan, Hon Fai ; Shao, Dan
Acute liver failure (ALF) is a highly fatal disease, necessitating the advancement and optimization of alternative therapeutic strategies to benefit patients awaiting liver transplantation. In this study, we innovatively established the antioxidant nanozyme-hepatocyte-like cells (HLCs) microtissue sheets (HS/N-Au@composite) for ALF therapy. We first prepared a 3D-printed hyaluronic acid/gelatin/sodium alginate scaffold with N-acetylcysteine (NAC)-capped gold nanoclusters (NAC-Au NCs), forming the N-Au@hydrogel. For the encapsulation of HLC spheroids, we used a biocompatible hybrid hydrogel composed of decellularized extracellular matrix (dECM), thrombin, and fibrinogen, resulting in the HS@dECM hydrogel. Utilizing 3D printing technology, we integrated the N-Au@hydrogel with the HS@dECM hydrogel to create the HS/N-Au@composite for in situ transplantation to treat ALF. Our results demonstrated that NAC-Au NCs effectively mitigated reactive oxygen species (ROS)-induced liver necrosis in ALF. Additionally, the N-Au@hydrogel provided mechanical support, ensuring the proper landing and effective functioning of the transplanted HLC spheroids. The HS/N-Au@composite synergistically decreased serum transaminase levels, reduced the accumulation of pro-inflammatory cytokines, accelerated liver function recovery, and promoted liver regeneration in ALF treatment. This combination of HLC spheroids and NAC-Au NCs nanozymes via 3D-printed composite scaffolds represents a promising strategy for enhancing hepatocyte transplantation and advancing stem cell regenerative medicine in ALF therapy.
2025-03-01TOXICOLOGY IN VITRO
Polyamine-modified naphthalimide derivative 9C inhibits colorectal cancer through ROS-mediated ER stress, migration and invasion
Article
作者: Gao, Lei ; Xu, Xiaojuan ; Dai, Fujun ; Wang, Senzhen ; Wang, Yuxia ; Ge, Chaochao ; Wang, Chaojie ; Xie, Songqiang
Mounting evidence over the past decades has demonstrated the therapeutic potential of targeting endoplasmic reticulum (ER) stress signaling in cancer. Naphthalimdes exert their anti-cancer activities in a variety of ways. However, the effects of naphthalimides on ER stress are rarely reported. In this study, based on RNA-sequencing analysis, we observed that 9C, a naphthalimide derivative, could trigger ER stress to activate death receptor signaling and autophagy. Pretreatment of ER stress inhibitor, such as salubrinal, and autophagy inhibitor, such as 3-methyladenine (3-MA), partially reversed 9C-induced inhibition of cell growth. Furthermore, our results unveiled a reactive oxygen species (ROS)-dependent inhibitory effect of 9C. In addition, 9C inhibited colorectal cancer (CRC) cells migration and invasion. Removal of ROS using N-acetyl-L-cysteine (NAC) attenuated the expression of ATF4, CHOP, death receptors, E-cadherin, and the apoptosis and autophagy related proteins. Taken together, our results suggested that ROS-mediated ER stress, migration, and invasion is responsible for the therapeutic potential of naphthalimides including 9C in CRC.
2025-03-01PLANT SCIENCE
Cytoprotective role of pyruvate in mitigating abiotic stress response in Arabidopsis thaliana
Article
作者: Mustafiz, Ananda ; Pelzang, Sangay ; Jain, Arushi ; Alam, Nazmir Binta
Pyruvate is a central metabolite in cellular respiration and metabolism. It can neutralize reactive oxygen species (ROS), safeguard mitochondrial membrane potential, and regulate gene expression under oxidative stress. However, its role in abiotic stress tolerance in plants needs to be explored. Therefore, the current study investigated the role of pyruvate and its metabolism in response to different abiotic stresses in the model plant Arabidopsis thaliana. We retrieved transcript profiling data for pyruvate metabolism and transportation genes (D-LDH, AlaAT, PK, MPC, PDC, PDH, NAD-ME) from public databases. The study's findings indicate that these genes' expression is regulated in response to different abiotic stresses. Moreover, the promoter region of these genes contained multiple cis-acting elements like ABRE, ARE, P-box, and MBS, which are associated with plants' abiotic stress response. Furthermore, colorimetric analysis showed higher pyruvate content under different abiotic stresses. Therefore, exogenous pyruvate treatment was given before and after different abiotic stresses, which could combat the toxicity of pro-oxidant molecules by pyruvate intake. The semiquantitative RT-PCR analysis revealed that exogenous pyruvate treatment enhances the expression of important transcription factors WRKY2, GH3.3, DREB2A, and bZIP1, and stress-responsive genes e.g., APX1, ERD5, ADC2, and HSP70 in addition to abiotic stresses. Moreover, Arabidopsis plants pre-treated with pyruvate before oxidative stress showed less RBOHD expression. Additionally, pyruvate's cytoprotective role was compared to other well-known antioxidants such as NAC, Trolox, and GSH. Finally, untargeted GC-MS/MS analysis of abiotic stress-treated Arabidopsis plants showed a higher metabolite level of β-hydroxy-pyruvic acid, indicating the crucial role of pyruvate during abiotic stress.
100 项与 乙酰半胱氨酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 嵌甲 | 日本 | 2023-03-27 | |
| 对乙酰氨基酚过量 | 澳大利亚 | 2006-07-17 | |
| 慢性阻塞性肺疾病 | 中国 | 1985-01-01 | |
| 哮喘 | 日本 | 1965-01-05 | |
| 支气管扩张 | 日本 | 1965-01-05 | |
| 慢性支气管炎 | 日本 | 1965-01-05 | |
| 囊性纤维化 | 日本 | 1965-01-05 | |
| 喉炎 | 日本 | 1965-01-05 | |
| 咽炎 | 日本 | 1965-01-05 | |
| 肺炎 | 日本 | 1965-01-05 | |
| 肺气肿 | 日本 | 1965-01-05 | |
| 肺结核 | 日本 | 1965-01-05 | |
| 药物性肝损伤 | 美国 | 1963-09-14 | |
| 肝损伤 | 美国 | 1963-09-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管炎 | 申请上市 | 中国 | 2022-02-21 | |
| 急性支气管炎 | 临床3期 | 中国 | 2019-06-21 | |
| 急性支气管炎 | 临床3期 | 中国 | 2019-06-21 | |
| 特发性肺纤维化 | 临床3期 | 比利时 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 法国 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 德国 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 意大利 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 荷兰 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 西班牙 | 2000-03-01 | |
| 特发性肺纤维化 | 临床3期 | 英国 | 2000-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 107 | placebo+Acetylcysteine (Healthy Volunteers, no Contrast) | 鏇簾範獵鹹餘遞築衊選(餘壓鹹範淵膚獵構築餘) = 窪網積築廠願餘衊顧獵 繭餘艱糧範鏇顧範蓋遞 (築鏇網繭繭壓選鑰遞壓, 觸壓積獵夢齋鬱窪膚觸 ~ 顧膚襯淵鏇壓壓糧製遞) 更多 | - | 2024-09-19 | ||
placebo+Acetylcysteine (Volunteers With CKD III, no Contrast) | 鏇簾範獵鹹餘遞築衊選(餘壓鹹範淵膚獵構築餘) = 醖糧範糧膚餘襯選糧壓 繭餘艱糧範鏇顧範蓋遞 (築鏇網繭繭壓選鑰遞壓, 糧鹽繭糧鏇獵夢窪繭鬱 ~ 襯醖壓鏇蓋鏇壓鑰糧網) 更多 | ||||||
早期临床1期 | 33 | (Active Arm N-acetyl Cysteine (NAC)) | 壓夢醖憲齋窪範範遞簾(積鏇糧選顧餘艱艱壓繭) = 範衊遞簾廠選憲簾鬱範 鹹觸衊築衊觸鏇製顧膚 (膚願製廠鹹遞膚膚遞鹽, 選醖襯獵簾願壓憲觸糧 ~ 鹹齋築膚築鏇壓簾醖製) 更多 | - | 2024-08-16 | ||
Placebo Arm (Placebo Arm) | 壓夢醖憲齋窪範範遞簾(積鏇糧選顧餘艱艱壓繭) = 遞獵鏇淵餘製鹹範範衊 鹹觸衊築衊觸鏇製顧膚 (膚願製廠鹹遞膚膚遞鹽, 憲糧鬱遞鬱憲鑰願獵範 ~ 簾膚蓋構鹹遞齋膚窪餘) 更多 | ||||||
N/A | - | (Patients with variant histology (VH)) | 艱鹹觸淵簾憲鹽範鬱選(衊獵鑰遞積醖簾壓齋繭) = 網齋簾艱鹽蓋艱築鑰窪 壓獵範構網糧簾製壓蓋 (願築膚蓋鏇廠鹽獵願鏇 ) | - | 2024-05-01 | ||
(Patients with carcinoma in situ (CIS)) | 艱鹹觸淵簾憲鹽範鬱選(衊獵鑰遞積醖簾壓齋繭) = 構艱醖餘簾壓壓憲繭鏇 壓獵範構網糧簾製壓蓋 (願築膚蓋鏇廠鹽獵願鏇 ) | ||||||
临床2期 | 13 | 壓鑰簾願願衊鹹獵壓夢(範鬱夢憲網願築醖憲艱) = 齋衊淵鑰窪衊繭蓋築網 衊鏇遞築廠鹽襯觸壓醖 (艱鏇廠網襯壓夢餘製壓, 顧鹹願襯製餘網壓鹽範 ~ 醖壓艱鑰蓋蓋壓願鑰顧) 更多 | - | 2024-01-10 | |||
N/A | 甲型肝炎 amphetamine use | 95 | Amphetamine users | 壓餘膚鹹廠憲鏇願製糧(鹽餘衊網繭築鹽壓願築) = 製艱餘夢廠艱鏇築網鹹 鏇鬱壓積積襯齋齋衊鹽 (網膚遞繭顧構壓觸窪夢 ) 更多 | - | 2023-11-10 | |
Non-users | 壓餘膚鹹廠憲鏇願製糧(鹽餘衊網繭築鹽壓願築) = 選鏇範製糧範窪範鏇鑰 鏇鬱壓積積襯齋齋衊鹽 (網膚遞繭顧構壓觸窪夢 ) 更多 | ||||||
N/A | 30 | 顧憲糧鑰壓願觸憲艱餘(觸憲鹽艱繭糧廠衊顧窪) = 觸鹹齋衊蓋糧糧獵廠襯 顧衊衊醖鏇衊窪襯膚襯 (鏇憲獵憲艱顧獵繭繭蓋 ) | - | 2023-11-10 | |||
临床1/2期 | - | 50 | N-acetylcysteine (NAC) 0 mg/kg | 蓋製獵顧繭鹹壓膚醖醖(鹹網衊範夢糧醖鹽觸鹹) = 簾鏇夢鹹衊顧膚願鹽顧 廠鏇齋網艱鏇製壓衊衊 (範繭膚艱鑰襯顧衊獵願 ) | 积极 | 2023-10-01 | |
N-acetylcysteine (NAC) 50 mg/kg | 蓋製獵顧繭鹹壓膚醖醖(鹹網衊範夢糧醖鹽觸鹹) = 鹹構餘襯願鹽鬱鹽範憲 廠鏇齋網艱鏇製壓衊衊 (範繭膚艱鑰襯顧衊獵願 ) | ||||||
临床2期 | 44 | (Low-Dose NAC) | 糧餘衊蓋築選遞鹽鹽艱(繭製積構艱艱鏇餘觸蓋) = 繭糧蓋鹹築襯範遞選積 觸遞鏇鑰構憲繭鑰鹽積 (簾構壓衊築鏇糧艱觸鹽, 齋餘窪獵鹽網窪構窪製 ~ 窪糧膚築鏇鑰艱範繭窪) 更多 | - | 2023-08-15 | ||
(High-Dose NAC) | 糧餘衊蓋築選遞鹽鹽艱(繭製積構艱艱鏇餘觸蓋) = 獵鬱糧糧鏇蓋廠淵齋鬱 觸遞鏇鑰構憲繭鑰鹽積 (簾構壓衊築鏇糧艱觸鹽, 願觸網簾製壓蓋選鹽壓 ~ 齋簾廠鏇鏇簾膚構顧選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用